Abstract
Cryoprecipitate is a concentrate of high-molecular-weight plasma proteins that precipitate when frozen plasma is slowly thawed at 1–6 °C. The concentrate contains factor VIII (antihemophilic factor), von Willebrand factor (vWF), fibrinogen, factor XIII, fibronectin, and small amounts of other plasma proteins. Clinical grade preparations of cryoprecipitate are mainly used to treat fibrinogen deficiency caused by acute bleeding or functional abnormalities of the fibrinogen protein. In the past, cryoprecipitate was used to treat von Willebrand disease and hemophilia A (factor VIII deficiency), but the availability of more highly purified coagulation factor concentrates or recombinant protein preparations has superseded the use of cryoprecipitate for these coagulopathies. Cryo-depleted plasma (“cryosupernatant”) is the plasma supernatant remaining following removal of the cryoprecipitate from frozen-thawed plasma. It contains all the other plasma proteins and clotting factors present in plasma that remain soluble during cold-temperature thawing of the plasma. This protocol describes the clinical-scale preparation of cryoprecipitate and cryo-depleted plasma for proteomic studies.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Pool JG, Gershgold EJ, Pappenhagen AR (1964) High-potency Antihaemophilic factor concentrate prepared from Cryoglobulin precipitate. Nature 203:312
Pool JG (1965) Preparation and testing of antihemophilic globulin (factor 8) sources for transfusion therapy in hemophilia. Description of a new sterile concentrate process for blood banks. Scand J Clin Lab Invest 17(84):70–77
Callum JL, Karkouti K, Lin Y (2009) Cryoprecipitate: the current state of knowledge. Transfus Med Rev 23:177–188
Erber WN, Perry DJ (2006) Plasma and plasma products in the treatment of massive haemorrhage. Best Pract Res Clin Haematol 19:97–112
Mason EC (1978) Thaw-siphon technique for production of cryoprecipitate concentrate of factor VIII. Lancet 2:15–17
Rock GA, Tittley P (1979) The effects of temperature variations on cryoprecipitate. Transfusion 19:86–89
Rock GA, Cruickshank WH, Tackaberry ES, Palmer DS (1979) Improved yields of factor VIII from heparinized plasma. Vox Sang 36:294–300
Shanbrom E, Owens WJ (2001) A novel method to enhance the formation of cryoprecipitate from fresh plasma. Blood 98:60a
Yousef H, Neurath D, Freedman M, Rock G (2006) Cryoprecipitate production: the use of additives to enhance the yield. Clin Lab Haematol 28:237–240
Fung MK, Grossman BJ, Hillyer CD, Westhoff CM, American Association Of Blood Banks (2014) Technical manual, 18th edn. American Association of Blood Banks, Bethesda, MD
Wensley RT, Snape TJ (1980) Preparation of improved cryoprecipitated factor VIII concentrate. A controlled study of three variables affecting the yield. Vox Sang 38:222–228
Meilin E, Sela S, Kristal B (2008) Heparin cryoprecipitation reduces plasma levels of non-traditional risk factors for atherosclerosis in vitro. Blood Purif 26:238–248
Elkassabany NM, Meny GM, Doria RR, Marcucci C (2008) Green plasma-revisited. Anesthesiology 108:764–765
Brunel V, Larson T, Peschanski N, Cauliez B (2012) Evaluation of haemolysis in emergency department samples requesting high sensitivity troponin T measurement. Ann Clin Biochem 49:509–510
Peffer K, de Kort WL, Slot E, Doggen CJ (2011) Turbid plasma donations in whole blood donors: fat chance? Transfusion 51:1179–1187
Green L, Backholer L, Wiltshire M, Platton S et al (2016) The hemostatic properties of thawed pooled cryoprecipitate up to 72 hours. Transfusion 56:1356–1361
Levitt J (2014) Standards of blood banks and transfusion services, 23rd edn. American Association of Blood Banks, Bethesda, MD, p 28
Prowse C (2009) Properties of pathogen-inactivated plasma components. Transfus Med Rev 23:124–133
Coene J, Devreese K, Sabot B, Feys HB et al (2014) Paired analysis of plasma proteins and coagulant capacity after treatment with three methods of pathogen reduction. Transfusion 54:1321–1331
Chan KS, Sparrow RL (2014) Microparticle profile and procoagulant activity of fresh-frozen plasma is affected by whole blood leukoreduction rather than 24-hour room temperature hold. Transfusion 54:1935–1944
George JN, Pickett EB, Heinz R (1986) Platelet membrane microparticles in blood bank fresh frozen plasma and cryoprecipitate. Blood 68:307–309
Morel O, Morel N, Jesel L, Freyssinet JM et al (2011) Microparticles: a critical component in the nexus between inflammation, immunity, and thrombosis. Semin Immunopathol 33:469–486
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer Science+Business Media LLC
About this protocol
Cite this protocol
Sparrow, R.L., Simpson, R.J., Greening, D.W. (2017). A Protocol for the Preparation of Cryoprecipitate and Cryo-depleted Plasma for Proteomic Studies. In: Greening, D., Simpson, R. (eds) Serum/Plasma Proteomics. Methods in Molecular Biology, vol 1619. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-7057-5_2
Download citation
DOI: https://doi.org/10.1007/978-1-4939-7057-5_2
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-7056-8
Online ISBN: 978-1-4939-7057-5
eBook Packages: Springer Protocols